Corcept Therapeutics (CORT) Cost of Revenue (2012 - 2026)

Corcept Therapeutics' Cost of Revenue history runs 15 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 19.98% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $13.5 million (up 25.18% YoY), while the FY2025 annual figure was $13.0 million, up 19.25% from the prior year.
• Cost of Revenue came in at $2.9 million for Q1 2026 at Corcept Therapeutics, up from $2.5 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $4.6 million in Q3 2025 to a low of $1.2 million in Q1 2022.
• A 5-year average of $2.3 million and a median of $2.4 million in 2025 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue surged 82.9% in 2024 and slipped 13.9% in 2025, its largest moves.
• Corcept Therapeutics' Cost of Revenue stood at $1.5 million in 2022, then advanced by 26.82% to $1.9 million in 2023, then soared by 57.49% to $3.0 million in 2024, then retreated by 13.9% to $2.5 million in 2025, then climbed by 13.28% to $2.9 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $2.9 million, $2.5 million, and $4.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison